Maze Therapeutics to Participate in the 2023 Jefferies Healthcare Conf...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: April 26, 2024

Dual Enrollment Helps High School Students Launch Rewarding Careers • BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report • 29 London Partners With US Media Company Bobi Media to Strengthen Market Offering • The Sallie Mae Fund Grants $75,000 to DC College Access Program to Support Higher Education Access and Completion • Emmy-winning Cyberchase Expands Digital Presence to Engage Every Kid, Everywhere Ahead of Season 15 Premiere • Nonprofits from Inception Fertility and Caden Lane Team Up to Expand Financial Accessibility to Fertility Care • LENNAR NOW SELLING THREE NEW-HOME COLLECTIONS AT JUNIPERS, SAN DIEGO'S RESORT-STYLE COMMUNITY FOR ACTIVE ADULTS AGED 55 AND BETT • Chase Opens Innovative Branch in Bronx’s Grand Concourse Neighborhood • Suzano 2023 annual report on Form 20-F • Manulife Investment Management Announces Forest Climate Fund's Second Close Bringing Total Commitments Up to $334.5 Million • Carbon Removal and Mariculture Legislation Moves Forward in California Assembly • United Imaging Healthcare Releases 2023 ESG Report, Advancing Mission of Equal Healthcare for All™ • Disneyland Resort Celebrates Return of Pixar Fest for a Limited Time, April 26-Aug. 4, 2024 • McCain Foods Plants 18,000 Trees in Wisconsin, Fulfilling 2022 Promise to Plover Community • Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions • In Support of PEPSI® x Mary J. Blige Strength of a Woman Partnership, The Brand Launches $100,000 Fund to Support Yonkers Wo • Coastal Carolina, Southwestern Law School, and Other Institutions Streamline Accessibility Workflows With YuJa's PDF Remediation • C2N Diagnostics Expands Into Japan Through Mediford Corporation Partnership With Precivity™ Blood Testing for Alzheimer&rs • United Imaging Healthcare releases 2023 annual report, with revenue growth of 23.52% • Operation HOPE and SBA Forge Strategic Alliance to Empower Small Businesses Across America

Maze Therapeutics to Participate in the 2023 Jefferies Healthcare Conference

SOUTH SAN FRANCISCO, Calif. , June 01 /Businesswire/ - Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that management will present a company overview at the 2023 Jefferies Healthcare Conference on Thursday, June 8, 2023, at 11:30 a.m. ET.

A live webcast of the presentation will be available here and in the news & press section of the company's website at www.mazetx.com. The webcast will be archived for 90 days following the presentation.

About Maze Therapeutics

Maze Therapeutics is a biopharmaceutical company that is harnessing the power of human genetics to transform the lives of patients, with a focus on genetically informed therapies for common diseases such as chronic kidney disease. Maze applies variant functionalization in tandem with advanced data science methods and a robust suite of research and development capabilities to advance a pipeline of novel precision medicines. Maze has developed the Maze Compass Platform^TM, a proprietary, purpose-built platform to understand and integrate the critical step of variant functionalization into each stage of drug development. Utilizing the Maze Compass Platform^TM, Maze is building a broad portfolio of wholly owned and partnered programs. Maze is based in South San Francisco. For more information, please visit mazetx.com, or follow us on LinkedIn and Twitter.